Despite the tumor immunotherapy (e.g. Anti-PD-1/PD-L1 immune checkpoint inhibitor) has benefited cancer patients to a certain extent, it still has great limitations, such as insensitivity, poor prognosis and side effects (Johnson et al., 2016; Moslehi et al., 2018). This evidence concerns the gene CD274 and neoplasm.